Skip to main content
Clinical Trials/NCT03711383
NCT03711383CompletedNot Applicable

The Effects of Inulin on Acetate Production and Human Substrate Metabolism

Maastricht University Medical Center1 site in 1 country24 target enrollmentStarted: February 20, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
24
Locations
1
Primary Endpoint
Plasma acetate concentrations (microM)

Study Overview

Brief Summary

Based on our hypothesis that orally administered resistant starch and inulin/beta glucan will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective:

To investigate the effects of an acute administration of inulin/beta glucan in combination with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
30 Years to 65 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • lean (BMI ≥ 20kg/m2 and ≤ 24.9kg/m2)
  • normoglycemic
  • aged 30 - 65 years
  • overweight/obese (BMI ≥ 25kg/m2 and ≤ 34.9kg/m2)
  • pre-diabetes
  • aged between 30 - 65 years.

Exclusion Criteria

  • diabetes mellitus
  • gastroenterological diseases or major abdominal surgery (allowed i.e.: - appendectomy, cholecystectomy)
  • lactose intolerance and other digestive disorders
  • cardiovascular disease, cancer, liver or kidney malfunction (determined -based on ALAT and creatinine levels, respectively)
  • disease with a life expectancy shorter than 5 years
  • Use of antibiotics 3 months prior inclusion
  • Use of probiotics or prebiotics

Outcomes

Primary Outcomes

Plasma acetate concentrations (microM)

Time Frame: At baseline and up to four hours after a high-fat mixed meal of each CID

Secondary Outcomes

  • Energy expenditure (in kJ/min) using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)(At baseline and up to four hours after a high-fat mixed meal of each CID)
  • Fat oxidation (in g/min) using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)(At baseline and up to four hours after a high-fat mixed meal of each CID)
  • Carbohydrate oxidation (in g/min) using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)(At baseline and up to four hours after a high-fat mixed meal of each CID)
  • Circulating hormone concentrations (Insulin, GLP-1, PYY)(At baseline and up to four hours after a high-fat mixed meal of each CID)
  • Circulating metabolite concentrations (Glucose, Free Fatty Acids, Triglycerides)(At baseline and up to four hours after a high-fat mixed meal of each CID)
  • Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)(At baseline and up to four hours after a high-fat mixed meal of each CID)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials